RPG Life Sciences Q2 FY27 Revenue Up 16.2% to ₹407.3 Cr; API Sales Surge 89.2%
RPG Life Sciences reported a 16.2% revenue growth for H1 FY27 to ₹407.3 crore. Q2 FY27 revenue increased by 16.5% to ₹181.7 crore. API sales surged 89.2% in Q2 FY27 to ₹28.0 crore. Market capitalization grew 64% in H1 FY27 to ₹5,023 crore.
The announcement includes strong financial results with significant year-on-year growth in revenue and a substantial increase in market capitalization, which are material events for investors.
The company reported strong revenue growth across segments, particularly in API sales, and a significant increase in market capitalization, indicating positive financial performance and market confidence.
RPG Life Sciences Limited has announced its unaudited financial results for the quarter and half-year ended September 30, 2026. The company reported a significant 16.2% increase in revenue from operations for H1 FY27, reaching ₹407.3 crore, compared to ₹350.6 crore in H1 FY26. This growth was accompanied by improved profitability, with Adjusted EBITDA margin at 20.6% and Adjusted PAT margin at 20.1% for H1 FY27.
For the second quarter of FY27, revenue from operations grew by 16.5% to ₹181.7 crore, up from ₹155.9 crore in Q2 FY26. The company also saw a substantial surge of 89.2% in API sales for Q2 FY27, amounting to ₹28.0 crore, compared to ₹14.8 crore in the prior year period. This strong performance in the API segment was also reflected in H1 FY27, with sales increasing by 58.5% to ₹54.6 crore.
Domestic Formulations, which constitute 69% of sales, grew by 11.6% in Q2 FY27 to ₹145.7 crore and by 13.0% in H1 FY27 to ₹278.3 crore. International Formulations, representing 18% of sales, saw a 6.4% increase in Q2 FY27 to ₹36.7 crore and a 7.0% rise in H1 FY27 to ₹71.7 crore.
The company's market capitalization has risen by 64% in H1 FY27, reaching ₹5,023 crore as of September 30, 2026, significantly outperforming the BSE Sensex and BSE Healthcare Index. RPG Life Sciences is focusing on several strategic pillars for future growth, including portfolio development, expanding market reach, driving productivity through digitalization, strengthening capacity, and integrating the API business.
What to do with a filing like this
RPG Life Sciences Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by RPG Life Sciences Limited. Read the original for the full detail.